17 citations
,
January 1993 in “Journal of Gastroenterology and Hepatology” This study found that recombinant IFN α-2b injections in patients with acute post-transfusion hepatitis C can suppress viral RNA and lead to normalization of serum ALT, though long-term prevention of chronicity remains unclear.
March 2016 in “International Journal of Infectious Diseases” This study reported that peginterferon alpha-2a showed high early and sustained virologic response rates in Albanian hemodialyzed patients with hepatitis C, despite causing several adverse effects.
209 citations
,
March 1989 in “Journal of The American Academy of Dermatology” This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.
4 citations
,
January 2024 in “Scientific Reports” In this study, researchers examined chronic hepatitis B patients and found that those undergoing interferon therapy reported higher quality of life than those on non-antiviral or nucleoside/nucleotide analogue treatments, despite potential side effects.
17 citations
,
February 2011 in “Expert Opinion on Drug Safety” This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.